Auteurs
Analysis
France
Racine
Analysis
France
Exploration
Accueil
Racine
Racine

Movement Disorders (revue) - Analysis (France)

Index « Auteurs » - entrée « I. Arnulf »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Héléne Grandjean < I. Arnulf < I. Berry  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 3.
Ident.Authors (with country if any)Title
000510 (2001) Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France]Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
000557 (1999) P. Damier [France] ; C. Jaillon [France] ; I. Clavier [France] ; I. Arnulf [France] ; A.-M. Bonnet [France] ; B.-P. Bejjani [France] ; Yves Agid [France]Dyskinesias assessment in phase II studies
000579 (1998) B.-P. Bejjani [France] ; P. Damier [France] ; I. Arnulf [France] ; S. Papadopoulos [France] ; A.-M. Bonnet [France] ; M. Vidailhet [France] ; Yves Agid [France] ; B. Pidoux [France] ; P. Cornu [France] ; D. Dormont [France] ; C. Marsault [France]Deep brain stimulation in Parkinson's disease : Opposite effects of stimulation in the pallidum

List of associated KwdEn.i

Nombre de
documents		Descripteur
3Human
3Parkinson disease
2Dose-Response Relationship, Drug
2Dyskinesia
2Humans
2Levodopa (adverse effects)
2Phase II trial
2Treatment
1Administration, Oral
1Adrenergic alpha-Antagonists (adverse effects)
1Adrenergic alpha-Antagonists (therapeutic use)
1Aged
1Antagonist
1Antiparkinson Agents (adverse effects)
1Antiparkinson Agents (therapeutic use)
1Biological Transport (physiology)
1Brain (metabolism)
1Case study
1Chemotherapy
1Clinical Protocols
1Dopamine (metabolism)
1Dopamine Agonists (adverse effects)
1Dopamine Agonists (pharmacokinetics)
1Dyskinesia, Drug-Induced (diagnosis)
1Dyskinesia, Drug-Induced (drug therapy)
1Dyskinesia, Drug-Induced (etiology)
1Exploration
1Female
1Idazoxan
1Idazoxan (adverse effects)
1Idazoxan (therapeutic use)
1Instrumental stimulation
1Levodopa (pharmacokinetics)
1Levodopa (therapeutic use)
1L‐DOPA, dyskinesia
1Male
1Middle Aged
1Neurologic Examination (drug effects)
1Pallidum
1Parkinson Disease (drug therapy)
1Parkinson's disease
1Pathophysiology
1Pilot Projects
1Sensitivity and Specificity
1Video recording
1idazoxan
1α2 receptors
1α2-Adrenergic receptor

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "I. Arnulf" 

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "I. Arnulf" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    I. Arnulf
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024